CN110770233A - 稠合双环类化合物及其在药物中的应用 - Google Patents

稠合双环类化合物及其在药物中的应用 Download PDF

Info

Publication number
CN110770233A
CN110770233A CN201880040262.7A CN201880040262A CN110770233A CN 110770233 A CN110770233 A CN 110770233A CN 201880040262 A CN201880040262 A CN 201880040262A CN 110770233 A CN110770233 A CN 110770233A
Authority
CN
China
Prior art keywords
amino
deuterium
ethyl
radical
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880040262.7A
Other languages
English (en)
Other versions
CN110770233B (zh
Inventor
潘圣强
马发城
张英勋
熊绍辉
杨新业
王晓军
张英俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong HEC Pharmaceutical
Original Assignee
Guangdong HEC Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong HEC Pharmaceutical filed Critical Guangdong HEC Pharmaceutical
Publication of CN110770233A publication Critical patent/CN110770233A/zh
Application granted granted Critical
Publication of CN110770233B publication Critical patent/CN110770233B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种稠合双环类化合物及其在药物中的应用，具体为一类新型的用作ASK1活性调节剂的稠合双环类化合物及其立体异构体，几何异构体，互变异构体，氮氧化物，水合物，溶剂化物，代谢产物，药学上可接受的盐或前药，以及所述化合物在制备治疗ASK1调节的疾病和/或病症的药物中的用途。还公开了一种含有该化合物的药物组合物和使用该化合物或其药物组合物治疗ASK1调节的疾病和/或病症的方法。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN201880040262.7A 2017-06-19 2018-06-15 稠合双环类化合物及其在药物中的应用 Active CN110770233B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710462252 2017-06-19
CN201710462252X 2017-06-19
PCT/CN2018/091392 WO2018233553A1 (zh) 2017-06-19 2018-06-15 稠合双环类化合物及其在药物中的应用

Publications (2)

Publication Number Publication Date
CN110770233A true CN110770233A (zh) 2020-02-07
CN110770233B CN110770233B (zh) 2022-07-26

Family

ID=64737474

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040262.7A Active CN110770233B (zh) 2017-06-19 2018-06-15 稠合双环类化合物及其在药物中的应用

Country Status (2)

Country Link
CN (1) CN110770233B (zh)
WO (1) WO2018233553A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461334A (zh) * 2020-11-27 2022-12-09 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209354A1 (en) 2017-05-12 2018-11-15 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
AU2019262016A1 (en) 2018-05-02 2020-11-19 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN111107848B (zh) * 2018-08-10 2023-05-23 江苏豪森药业集团有限公司 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
CN110818683B (zh) * 2018-08-10 2023-04-14 中国科学院上海药物研究所 2-吡啶取代脲结构小分子化合物及其合成和应用
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11345699B2 (en) 2018-11-19 2022-05-31 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020198214A1 (en) 2019-03-25 2020-10-01 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020220562A1 (zh) * 2019-04-29 2020-11-05 上海和誉生物医药科技有限公司 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用
CN114585616B (zh) * 2019-08-19 2024-01-16 广东东阳光药业股份有限公司 酰胺衍生物及其在药物中的应用
CN111808079A (zh) * 2020-08-05 2020-10-23 中国药科大学 吲哚类ask1小分子抑制剂及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016131A1 (fr) * 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique à cycles fusionnés
CN101878212A (zh) * 2007-08-31 2010-11-03 默克雪兰诺有限公司 三唑并吡啶化合物及其作为ask抑制剂的用途
CN102482257A (zh) * 2009-07-13 2012-05-30 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
CN102834393A (zh) * 2010-02-03 2012-12-19 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
WO2016025474A1 (en) * 2014-08-13 2016-02-18 Gilead Sciences, Inc. Methods of treating pulmonary hypertension
CN111094250A (zh) * 2017-03-03 2020-05-01 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016131A1 (fr) * 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique à cycles fusionnés
CN101878212A (zh) * 2007-08-31 2010-11-03 默克雪兰诺有限公司 三唑并吡啶化合物及其作为ask抑制剂的用途
CN102482257A (zh) * 2009-07-13 2012-05-30 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
CN102834393A (zh) * 2010-02-03 2012-12-19 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
WO2016025474A1 (en) * 2014-08-13 2016-02-18 Gilead Sciences, Inc. Methods of treating pulmonary hypertension
CN111094250A (zh) * 2017-03-03 2020-05-01 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TONY S. GIBSON ET AL.，: "Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461334A (zh) * 2020-11-27 2022-12-09 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途

Also Published As

Publication number Publication date
WO2018233553A1 (zh) 2018-12-27
CN110770233B (zh) 2022-07-26

Similar Documents

Publication Publication Date Title
CN110770233B (zh) 稠合双环类化合物及其在药物中的应用
CN109400625B (zh) 稠合双环类化合物及其在药物中的应用
CN105884758B (zh) 三环化合物及其在药物中的应用
CN110036005B (zh) 酰胺衍生物及其在药物中的应用
CN108430998B (zh) 氮杂双环衍生物及其制备方法和用途
CN107686486B (zh) 含氮三环化合物及其在药物中的应用
CN109563071B (zh) 作为atf4途径抑制剂的化学化合物
CN102036981B (zh) 取代的4-羟基嘧啶-5-甲酰胺
CN113637005A (zh) 用于癌症治疗的kras抑制剂
TW201605799A (zh) 溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑
CN101842376A (zh) 四环吲哚衍生物及其用于治疗或预防病毒感染
TW201446760A (zh) 作爲β－分泌酶抑制劑之全氟化環丙基稠合１，３－□－２－胺化合物及其用途
KR20090094154A (ko) Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
EA032477B1 (ru) Ингибиторы вирусной репликации
TW201446758A (zh) 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途
CN112771027A (zh) 溶血磷脂酸受体拮抗剂及其制备方法
CN109988093B (zh) 抑制ssao/vap-1的胺类化合物及其在医药上的应用
CN110128432B (zh) 含氮三环化合物及其在药物中的应用
CN111138458A (zh) 具有hiv复制抑制作用的含氮三环性衍生物
CN111163766A (zh) Ahr抑制剂和其用途
CN110563722A (zh) 吡啶或哒嗪并环化合物及其应用
CN113164475A (zh) Dyrk1a的大环抑制剂
KR20220051226A (ko) 아자헤테로아릴 화합물 및 이의 용도
CN110964023A (zh) 稠合四环类化合物及其在药物中的应用
TW201441233A (zh) 作爲β－分泌酶抑制劑之稠合多環的碸化合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No. 1 Industrial North Road, Songshan Industrial Park, Songshan, Guangdong, Dongguan, Hubei

Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd.